Drugs / AEG35156
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00372736 | Jul 2006 → Mar 2009 | cancer of unknown primary site | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT00385775 | Jun 2006 → Oct 2008 | cancer of unknown primary site | Aegera Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT00357747 | Jun 2005 → Sep 2006 | cancer of unknown primary site | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT00882869 | Mar 2009 → Mar 2011 | hepatocellular carcinoma | Aegera Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00768339 | Sep 2008 → Jun 2011 | B-cell chronic lymphocytic leukemia | Aegera Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT00558545 | Nov 2007 → May 2009 | breast carcinoma | Aegera Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT00558922 | Sep 2007 → Aug 2009 | non-small cell lung carcinoma | Aegera Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT00557596 | Sep 2007 → Nov 2009 | carcinoma, pancreatic neoplasm | Aegera Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT00363974 | Oct 2005 → Mar 2009 | acute myelomonocytic leukemia M4 | Aegera Therapeutics | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01018069 Comparator | Nov 2009 → Oct 2010 | leukemia | Aegera Therapeutics | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AEG35156 | “An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy” NCT00363974 ↗9“AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors” NCT00372736 ↗ |
| Action | Inhibit | “effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy” NCT00363974 ↗ |
| Modality | Antisense oligonucleotide | “XIAP Antisense AEG35156” NCT00363974 ↗ |
| Route | Intravenous | “Patients receive AEG35156 IV continuously on days -2 and -1.” NCT00357747 ↗ |
| Target | XIAP | “effectively reduces levels of a protein (XIAP)” NCT00363974 ↗ |